Heron Therapeutics (NASDAQ:HRTX) Posts Earnings Results

Heron Therapeutics (NASDAQ:HRTX) announced its earnings results on Monday. The biotechnology company reported ($0.03) EPS for the quarter, FiscalAI reports. Heron Therapeutics had a negative return on equity of 265.11% and a negative net margin of 22.52%.The business had revenue of $37.67 million for the quarter, compared to analyst estimates of $42.19 million.

Here are the key takeaways from Heron Therapeutics’ conference call:

• Heron withdrew its 2026 financial guidance of $173 million-$183 million in net product sales and $10 million-$20 million in adjusted EBITDA, citing uncertainty around potential generic CINVANTI entry, reduced spending, and strategic alternatives.
• CINVANTI revenue was $21.8 million, down approximately 10% year over year amid branded competition. Heron is appealing a June court decision and preparing for potential generic competition, although management said launch timing and manufacturing and reimbursement factors remain uncertain.
• The acute-care portfolio continued to grow: ZYNRELEF revenue increased 35% year over year to $11.1 million, while APONVIE rose 74% to $4.2 million and reached 23% share of the surgical NK1 segment.
• Second-quarter revenue increased to $37.7 million from $34.7 million in the first quarter, with adjusted EBITDA of $3.2 million; however, the company posted a $5.5 million net loss and ended the quarter with $42.7 million in cash and short-term investments.
• To preserve liquidity and meet revised debt requirements, Heron paused planned second-half sales-force expansion, tightened spending, and agreed to pay down up to $17.5 million of principal under its amended Hercules credit facility. The company is also evaluating strategic alternatives without a set timetable or assurance of a transaction.

Heron Therapeutics Stock Performance

Shares of HRTX traded up $0.01 during trading hours on Wednesday, hitting $0.33. The company had a trading volume of 938,226 shares, compared to its average volume of 2,550,823. The business has a fifty day moving average of $0.44 and a 200-day moving average of $0.82. The company has a quick ratio of 1.51, a current ratio of 2.53 and a debt-to-equity ratio of 17.51. The firm has a market cap of $63.03 million, a price-to-earnings ratio of -1.75 and a beta of 1.65. Heron Therapeutics has a 12 month low of $0.30 and a 12 month high of $1.57.

Institutional Trading of Heron Therapeutics

Institutional investors have recently added to or reduced their stakes in the company. Headlands Technologies LLC grew its stake in shares of Heron Therapeutics by 158.3% in the fourth quarter. Headlands Technologies LLC now owns 51,287 shares of the biotechnology company’s stock valued at $67,000 after acquiring an additional 31,431 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Heron Therapeutics by 45.9% in the fourth quarter. Wells Fargo & Company MN now owns 179,620 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 56,488 shares in the last quarter. State of Wyoming acquired a new stake in shares of Heron Therapeutics in the fourth quarter valued at approximately $76,000. Glenmede Investment Management LP boosted its stake in shares of Heron Therapeutics by 49.9% in the third quarter. Glenmede Investment Management LP now owns 105,326 shares of the biotechnology company’s stock valued at $133,000 after buying an additional 35,076 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in Heron Therapeutics during the second quarter worth approximately $99,000. 80.01% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Heron Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Heron Therapeutics to a “sell” rating in a report on Saturday. Zacks Research raised shares of Heron Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, August 3rd. HC Wainwright cut shares of Heron Therapeutics from a “buy” rating to a “neutral” rating in a research note on Tuesday. Finally, Needham & Company LLC lowered shares of Heron Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, June 2nd. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $2.00.

About Heron Therapeutics

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.